Table 4.
Adverse Event, n (%) | Cabotegravir 150 mg (n = 40) | Cabotegravir Placebo (n = 39) | Moxifloxacin 400 mg (n = 36) |
---|---|---|---|
Any adverse event | 13 (33) | 16 (41) | 12 (33) |
Dermatitis contact | 6 (15) | 9 (23) | 2 (6) |
Headache | 1 (3) | 2 (5) | 2 (6) |
Nausea | 0 | 0 | 2 (6) |
Alanine aminotransferase increased | 1 (3) | 1 (3) | 0 |
Blood creatine phosphokinase increased | 0 | 1 (3) | 1 (3) |